With the CF Research News, we aim to bridge the gap between people with CF and the researchers investigating CF and how best to treat those with the condition.
We want to provide access to patients, parents, relatives, friends and caregivers of patients with CF to all scientific work mainly published in the Journal of Cystic Fibrosis (JCF).

All PDF files published hereunder are lay version summaries of work published in the JCF.

March 2026

Title: Cystic Fibrosis Year in Review 2025
Authors
Sophia T. Pallenberg, Ester Zamarrón de Lucas, Andrea Párniczky, Raquel Lopes de Bragança
References
2026 Mar;25(2):198-203.  doi: 10.1016/j.jcf.2026.02.010.
Keywords
Cystic fibrosis, Year in review, CFTR modulators, ETI, Lung infections, Inflammation, Emerging therapies
File JCF-D-26-00083_FINAL_Lopes de Braganca_30032026.docx
Title: What Influences COVID-19 Severity After Transplant: Lessons From a Global Study
Authors
Julie Semenchuk, Yumi Naito, Susan C. Charman, Siobhán B Carr, etc, Anne L. Stephenson on behalf of the Global CF Registry Collaboration
References
2026 Mar 11:S1569-1993(26)00038-X.  doi: 10.1016/j.jcf.2026.02.009
Keywords
COVID-19, Cystic fibrosis, Pandemic, SARS-CoV-2, Coronavirus, transplantation
File JCF-D-25-00322R1_FINAL_Semenchuk_19032026.docx

March 2026

Title: Changes in Body Weight and Cholesterol After Starting ETI: A Scoping Review
Authors
Anna Walsh, Clodagh Landers, Niamh Lucey, Oonagh Griffin, Suzanne Carter, Clare Corish
References
2026 Mar 20:S1569-1993(26)00044-5.  doi: 10.1016/j.jcf.2026.02.015.
Keywords
Cystic fibrosis, Elexacaftor/tezacaftor/ivacaftor, ETI, Body mass index, Body composition, Serum lipids, Cholesterol
File JCF-D-25-00486R2_FINAL_Walsh_30032026.docx
Title: How many exacerbations someone had last year predicts how many they will have this year, even when taking a modulator
Authors
D. R. VanDevanter, C. O'Rourke, M. W. Konstan, J. P. Clancy, N. Mayer-Hamblett
References
2026 Mar;25(2):204-209.  doi: 10.1016/j.jcf.2025.11.010. Epub 2025 Nov 29
Keywords
Cystic fibrosis, Pulmonary exacerbations, CFTR modulators, Elexacaftor/tezacaftor/ivacaftor, Risk prediction, patient registry, clinical trials
File JCF-D-25-00377R1_FINAL_VanDevanter_30032026.docx
Title: Is the multiple breath washout test reproducible in adults with cystic fibrosis?
Authors
Chantal Darquenne, Janelle M. Fine, Ann R. Elliott, Douglas J. Conrad and Rebecca J. Theilmann
References
2026 Mar;25(2):272-278.  doi: 10.1016/j.jcf.2026.02.003. Epub 2026 Feb 11.
Keywords
Cystic fibrosis, Lung function, Multiple breath washouts
File JCF-D-25-00473R2_FINAL_Darquenne_24022026.docx
Title: Different Drugs, Different Results: What New CF Treatments Can Offer
Authors
Noelia Rodriguez Mier, Isabelle Callebaut, Marijke Proesmans, Eva Van Braeckel, Stephanie Van Biervliet, Mieke Boon, Anabela Santo Ramalho, François Vermeulen
References
2026 Mar;25(2):314-318. doi: 10.1016/j.jcf.2025.12.018. Epub 2025 Dec 31.
Keywords
CFTR modulators, Cystic fibrosis, Elexacaftor, In vitro functional assays, Patientderived intestinal organoids, Personalized therapy, Rare CFTR variants, Theratyping, Vanzacaftor
File JCF-D-25-00321R1_FINAL_Rodriguez Mier_26012026.docx